Additional information:
Lanraplenib monosuccinate (GS-9876 monosuccinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib monosuccinate (GS-9876 monosuccinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.|Product information|CAS Number: 1800046-97-2|Molecular Weight: 561.59|Formula: C27H31N9O5|Chemical Name: 6-[8-({4-[4-(oxetan-3-yl)piperazin-1-yl]phenyl}amino)imidazo[1,2-a]pyrazin-6-yl]pyrazin-2-amine; butanedioic acid|Smiles: NC1=CN=CC(=N1)C1=CN2C=CN=C2C(NC2C=CC(=CC=2)N2CCN(CC2)C2COC2)=N1.{{Vobramitamab} medchemexpress|{Vobramitamab} Antibody-drug Conjugate/ADC Related|{Vobramitamab} Technical Information|{Vobramitamab} Purity|{Vobramitamab} custom synthesis|{Vobramitamab} Autophagy} OC(=O)CCC(O)=O|InChiKey: DVFRSTNNWJHWGW-UHFFFAOYSA-N|InChi: InChI=1S/C23H25N9O.{{Isoniazid} web|{Isoniazid} Autophagy|{Isoniazid} Biological Activity|{Isoniazid} References|{Isoniazid} supplier|{Isoniazid} Cancer} C4H6O4/c24-21-12-25-11-19(28-21)20-13-32-6-5-26-23(32)22(29-20)27-16-1-3-17(4-2-16)30-7-9-31(10-8-30)18-14-33-15-18;5-3(6)1-2-4(7)8/h1-6,11-13,18H,7-10,14-15H2,(H2,24,28)(H,27,29);1-2H2,(H,5,6)(H,7,8)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 125 mg/mL (222.PMID:23522542 58 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Lanraplenib monosuccinate (GS-9876 monosuccinate) inhibits anti-IgM stimulated phosphorylation of AKT, BLNK, BTK, ERK, MEK, and PKCδ in human B cells with EC50 values of 24-51 nM. Lanraplenib monosuccinate inhibits anti-IgM mediated CD69 and CD86 expression on B-cells (EC50=112±10 nM and 164±15 nM, respectively) and anti-IgM /anti-CD40 co-stimulated B cell proliferation (EC50=108±55 nM). In human macrophages, Lanraplenib monosuccinate inhibits IC-stimulated TNFα and IL-1β release (EC50=121±77 nM and 9±17 nM, respectively). Lanraplenib monosuccinate (GS-9876 monosuccinate) inhibits glycoprotein VI (GPVI)-induced phosphorylation of linker for activation of T cells and phospholipase Cγ2, platelet activation and aggregation in human whole blood, and platelet binding to collagen under arterial flow.|Products are for research use only. Not for human use.|

Additional information:
Pifithrin-alpha is a p53 inactivator.{{Farletuzumab ecteribulin} MedChemExpress|{Farletuzumab ecteribulin} Antibody-drug Conjugate/ADC Related|{Farletuzumab ecteribulin} Technical Information|{Farletuzumab ecteribulin} References|{Farletuzumab ecteribulin} supplier|{Farletuzumab ecteribulin} Autophagy} It also has neuroprotective activity against strokes.PMID:24732841 |Product information|CAS Number: 63208-82-2|Molecular Weight: 367.30|Formula: C16H19BrN2OS|Chemical Name: 2-(2-imino-2,3,4,5,6,7-hexahydro-1,3-benzothiazol-3-yl)-1-(4-methylphenyl)ethan-1-one hydrobromide|Smiles: Br.CC1C=CC(=CC=1)C(=O)CN1C(=N)SC2CCCCC1=2|InChiKey: HAGVCKULCLQGRF-UHFFFAOYSA-N|InChi: InChI=1S/C16H18N2OS.BrH/c1-11-6-8-12(9-7-11)14(19)10-18-13-4-2-3-5-15(13)20-16(18)17;/h6-9,17H,2-5,10H2,1H3;1H|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥360 days if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|Products are for research use only. Not for human use.|

Additional information:
Monoacylglycerol lipase inhibitor 1 is a potent monoacylglycerol lipase inhibitor (compound 13).|Product information|CAS Number: 2714570-98-4|Molecular Weight: 356.46|Formula: C21H28N2O3|Smiles: CC(C)C1C=CC(=CC=1)[C@@H]1C[C@@H](C1)N(C)C(=O)[C@@H]1C[C@@]2(COC(=O)N2)C1|InChiKey: BKAUVVYBHJYFLY-BXCOXIEISA-N|InChi: InChI=1S/C21H28N2O3/c1-13(2)14-4-6-15(7-5-14)16-8-18(9-16)23(3)19(24)17-10-21(11-17)12-26-20(25)22-21/h4-7,13,16-18H,8-12H2,1-3H3,(H,22,25)/t16-,17-,18+,21+|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: To be determined|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|References:|Ram W Sabnis, et al. Novel Aminocyclobutanes as Monoacylglycerol Lipase Modulators. ACS Med Chem Lett. 2022 Feb 1;13(2):162-163.Products are for research use only. Not for human use.|

Additional information:
GDC-1971 (compound 199) is a SHP2 inhibitor.|Product information|CAS Number: 2377352-49-1|Molecular Weight: 454.53|Formula: C25H26N8O|Smiles: N[C@@H]1C2=CC=CC=C2OC21CCN(CC2)C1=CN=C2C(NN=C2N2CCCC3=NC=CC=C23)=N1|InChiKey: RGCGBFIARQENML-JOCHJYFZSA-N|InChi: InChI=1S/C25H26N8O/c26-22-16-5-1-2-8-19(16)34-25(22)9-13-32(14-10-25)20-15-28-21-23(29-20)30-31-24(21)33-12-4-6-17-18(33)7-3-11-27-17/h1-3,5,7-8,11,15,22H,4,6,9-10,12-14,26H2,(H,29,30,31)/t22-/m1/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: To be determined|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|References:|Alexander M, et al. Shp2 phosphatase inhibitors and methods of use thereof. Patent WO2019183367A1.Products are for research use only. Not for human use.|

Additional information:
(R, S)-CFT8634 is a selective and orally active BRD9 protein degrader. (R, S)-CFT8634 has the potential for the research of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation (extracted from patent WO2021178920A1, compound 176). (R, S)-CFT8634 is a selective and orally active BRD9 protein degrader. (R, S)-CFT8634 has the potential for the research of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation (extracted from patent WO2021178920A1, compound 176)[1].|Product information|CAS Number: 2704619-11-2|Molecular Weight: 710.79|Formula: C37H45F3N6O5|Smiles: CN1C=C(C2C=C(OC)C(CN3CC(F)(F)[C@@H](CC3)N3CCN(CC3)C3=CC=C(C=C3F)N[C@H]3CCC(=O)NC3=O)=C(C=2)OC)C(C)=C(C)C1=O|InChiKey: GNRGNRCQXHMQQV-RYCFQHDISA-N|InChi: InChI=1S/C37H45F3N6O5/c1-22-23(2)36(49)43(3)19-26(22)24-16-31(50-4)27(32(17-24)51-5)20-44-11-10-33(37(39,40)21-44)46-14-12-45(13-15-46)30-8-6-25(18-28(30)38)41-29-7-9-34(47)42-35(29)48/h6,8,16-19,29,33,41H,7,9-15,20-21H2,1-5H3,(H,42,47,48)/t29-,33+/m0/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: To be determined|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|Products are for research use only. Not for human use.|

Additional information:
MIPS-521 is a positive allosteric modulator of the A1R, exhibits analgesic efficacy in rats in vivo through modulation of the increased levels of endogenous adenosine that occur in the spinal cord of rats with neuropathic pain. We also report the structure of the A1R co-bound to adenosine, MIPS521 and a Gi2 heterotrimer, revealing an extrahelical lipid-detergent-facing allosteric binding pocket that involves transmembrane helixes 1, 6 and 7. Molecular dynamics simulations and ligand kinetic binding experiments support a mechanism whereby MIPS521 stabilizes the adenosine-receptor-G protein complex.|Product information|CAS Number: 1146188-19-3|Molecular Weight: 449.80|Formula: C19H10ClF6NOS|Chemical Name: 4-[3, 5-bis(trifluoromethyl)phenyl]-3-(4-chlorobenzoyl)thiophen-2-amine|Smiles: NC1SC=C(C=1C(=O)C1C=CC(Cl)=CC=1)C1C=C(C=C(C=1)C(F)(F)F)C(F)(F)F|InChiKey: IVHJBJJHYFIUOA-UHFFFAOYSA-N|InChi: InChI=1S/C19H10ClF6NOS/c20-13-3-1-9(2-4-13)16(28)15-14(8-29-17(15)27)10-5-11(18(21,22)23)7-12(6-10)19(24,25)26/h1-8H,27H2|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: To be determined|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Vigabatrin} site|{Vigabatrin} Neuronal Signaling|{Vigabatrin} Protocol|{Vigabatrin} Purity|{Vigabatrin} custom synthesis|{Vigabatrin} Autophagy} |Shelf Life: ≥12 months if stored properly.{{Estramustine phosphate} web|{Estramustine phosphate} Cytoskeleton|{Estramustine phosphate} Protocol|{Estramustine phosphate} In Vivo|{Estramustine phosphate} custom synthesis|{Estramustine phosphate} Autophagy} |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.PMID:23819239 |Drug Formulation: To be determined|HS Tariff Code: 382200|References:|Draper-Joyce CJ, Bhola R, Wang J, Bhattarai A, Nguyen ATN, Cowie-Kent I, O’Sullivan K, Chia LY, Venugopal H, Valant C, Thal DM, Wootten D, Panel N, Carlsson J, Christie MJ, White PJ, Scammells P, May LT, Sexton PM, Danev R, Miao Y, Glukhova A, Imlach WL, Christopoulos A. Positive allosteric mechanisms of adenosine A1 receptor-mediated analgesia. Nature. 2021 Sep;597(7877):571-576.Products are for research use only. Not for human use.|

Additional information:
SM-276001 is a potent selective TLR7 agonist that can induce antitumor immune responses. SM-276001 is an orally active interferon (IFN) inducer.|Product information|CAS Number: 473930-22-2|Molecular Weight: 327.38|Formula: C16H21N7O|Chemical Name: 6-amino-2-(butylamino)-9-[(6-methylpyridin-3-yl)methyl]-8,9-dihydro-7H-purin-8-one|Smiles: CC1=CC=C(CN2C(=O)NC3=C(N)N=C(NCCCC)N=C23)C=N1|InChiKey: UEIOLEMXCBOQAX-UHFFFAOYSA-N|InChi: InChI=1S/C16H21N7O/c1-3-4-7-18-15-21-13(17)12-14(22-15)23(16(24)20-12)9-11-6-5-10(2)19-8-11/h5-6,8H,3-4,7,9H2,1-2H3,(H,20,24)(H3,17,18,21,22)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 125 mg/mL (381.82 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.{{Sarolaner} medchemexpress|{Sarolaner} Anti-infection|{Sarolaner} Biological Activity|{Sarolaner} Description|{Sarolaner} manufacturer|{Sarolaner} Epigenetics} |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.{{Coelenterazine} site|{Coelenterazine} NF-κB|{Coelenterazine} Biological Activity|{Coelenterazine} Description|{Coelenterazine} custom synthesis|{Coelenterazine} Cancer} |Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|SM-276001 (1 nM-10 μM) dose-dependently activates NF-κB through human TLR7.PMID:23672196 |In Vivo:|SM-276001 demonstrates potent IFN-inducing activity at a dose of 0.1 mg/kg by oral administration in mice. Oral administration of SM-276001, leads to the induction of an inflammatory cytokine and chemokine milieu and to the activation of a diverse population of immune effector cells including T and B lymphocytes, NK and NKT cells. SM-276001 (3 mg/kg PO biweekly) significantly inhibits tumor growth in the Renca renal cell cancer and CT26 colorectal models. SM-276001 (orally; 0.1, 1 or 10 mg/kg) leads to the activation of a diverse population of spleen-resident immune effector cells in Balb/c and C57BL/6J mice. When administered at 1 mg/kg or greater, the plasma concentration of SM-276001 exceeds the MEC of 30 nM.|Products are for research use only. Not for human use.|

Additional information:
GGTI-2418 is a highly potent, competitive, and selective geranylgeranyltransferase I (GGTase I) inhibitor. GGTI-2418 inhibits GGTase I and FTase activities with IC50s of 9.5 nM and 53 μM, respectively. GGTI-2418 also increases p27(Kip1) and induces significant regression of breast tumors.|Product information|CAS Number: 501010-06-6|Molecular Weight: 441.52|Formula: C23H31N5O4|Chemical Name: (2S)-2-{[(2S)-2-benzyl-4-[(5-methyl-1H-imidazol-4-yl)methyl]-3-oxopiperazine-1-carbonyl]amino}-4-methylpentanoic acid|Smiles: CC1NC=NC=1CN1CCN([C@@H](CC2C=CC=CC=2)C1=O)C(=O)N[C@@H](CC(C)C)C(O)=O|InChiKey: COLCNDRDBCLVOC-ICSRJNTNSA-N|InChi: InChI=1S/C23H31N5O4/c1-15(2)11-18(22(30)31)26-23(32)28-10-9-27(13-19-16(3)24-14-25-19)21(29)20(28)12-17-7-5-4-6-8-17/h4-8,14-15,18,20H,9-13H2,1-3H3,(H,24,25)(H,26,32)(H,30,31)/t18-,20-/m0/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 125 mg/mL (283.11 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|GGTI-2418 inhibits GGTase I and FTase activities with IC50s of 9.{{Lebrikizumab} site|{Lebrikizumab} Interleukin Related|{Lebrikizumab} Biological Activity|{Lebrikizumab} Purity|{Lebrikizumab} supplier|{Lebrikizumab} Epigenetics} 5±2.{{Adapalene} site|{Adapalene} Apoptosis|{Adapalene} Technical Information|{Adapalene} Formula|{Adapalene} manufacturer|{Adapalene} Epigenetics} 0 nM and 53±11 μM, respectively, a 5,600-fold selectivity toward inhibition of GGTase I versus FTase.PMID:24423657 GGTI-2418 demonstrates competitive inhibition of GGTase I against the H-Ras-CVLL protein with a Ki of 4.4±1.6 nM. GGTi-2418 (10-15 μM; 16 hours) treatment delocalizes FBXL2 and stabilizes IP3R3.|In Vivo:|GGTI-2418 (100 mg/kg daily or 200 mg/kg every third day; 15 days) significantly inhibits the growth of breast tumor xenografts in nude mice with MDA-MB-231 xenografts. GGTI-2418 (100 mg/kg daily; 5 days) induces regression of ErbB2-driven mammary tumors in ErbB2 transgenic mice. GGTI-2418 inhibits the geranylgeranylation of Rap1 and causes a dramatic decrease in S473 phosphorylation of Akt. GGTI-2418 also upregulates p27 levels in vivo.|Products are for research use only. Not for human use.|

Additional information:
Sulfo-ara-F-NMN (CZ-48) is a mimetic of nicotinamide mononucleotide (NMN). Sulfo-ara-F-NMN acts selectively, activating SARM1 but inhibiting CD38 (IC50 around 10 μM). Sulfo-ara-F-NMN induces intracellular cyclic ADP-ribose (cADPR) production.|Product information|CAS Number: 1374663-29-2|Molecular Weight: 352.28|Formula: C11H14FN2O6PS|Chemical Name: 3-carbamoyl-1-[(2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-({[hydroxy(oxido)sulfanylidene-λ⁵-phosphanyl]oxy}methyl)oxolan-2-yl]-1λ⁵-pyridin-1-ylium|Smiles: NC(=O)C1C=[N+](C=CC=1)[C@@H]1O[C@H](COP([O-])(O)=S)[C@@H](O)[C@@H]1F|InChiKey: SIQYQBAPGWSZQF-PKIKSRDPSA-N|InChi: InChI=1S/C11H14FN2O6PS/c12-8-9(15)7(5-19-21(17,18)22)20-11(8)14-3-1-2-6(4-14)10(13)16/h1-4,7-9,11,15H,5H2,(H3-,13,16,17,18,22)/t7-,8+,9-,11-/m1/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 200 mg/mL (567.{{Nystatin} medchemexpress|{Nystatin} Apoptosis|{Nystatin} Protocol|{Nystatin} In Vitro|{Nystatin} supplier|{Nystatin} Cancer} 73 mM; Need ultrasonic).{{Lansoprazole} web|{Lansoprazole} Membrane Transporter/Ion Channel|{Lansoprazole} Protocol|{Lansoprazole} In Vivo|{Lansoprazole} custom synthesis|{Lansoprazole} Epigenetic Reader Domain} |Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.PMID:22664133 |Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Sterile alpha and Toll/interleukin-1 receptor motif-containing 1 (SARM1) is an adaptor protein in the Toll-like receptor pathway. Sulfo-ara-F-NMN activates SARM1 to produce cyclic ADP-ribose and induces non-apoptotic cell death.|Products are for research use only. Not for human use.|

Additional information:
TFAX 568, SE is an orange fluorescent dye and exhibits pH-insensitivity over a very broad range (pH in the 4-10).{{Pretomanid} web|{Pretomanid} Bacterial|{Pretomanid} Purity & Documentation|{Pretomanid} In Vivo|{Pretomanid} custom synthesis|{Pretomanid} Cancer} TFAX 568, SE yields exceptionally bright, photostable conjugates with proteins or antibodies (such as goat anti-mouse IgG).|Product information|CAS Number: 878549-44-1|Molecular Weight: 791.80|Formula: C37H33N3O13S2|Chemical Name: 6-(2-carboxy-4-{[(2,5-dioxopyrrolidin-1-yl)oxy]carbonyl}phenyl)-2,2,10,10-tetramethyl-4-(sulfomethyl)-8-(sulfonatomethyl)-2,10-dihydro-1H-13-oxa-1,11-diazapentacen-11-ium|Smiles: CC1(C)C=C(CS(O)(=O)=O)C2=CC3=C(C=C2N1)OC1=CC2=[NH+]C(C)(C)C=C(CS([O-])(=O)=O)C2=CC1=C3C1=CC=C(C=C1C(O)=O)C(=O)ON1C(=O)CCC1=O|InChiKey: DJLBKHHGFYXTRY-UHFFFAOYSA-N|InChi: InChI=1S/C37H33N3O13S2/c1-36(2)14-19(16-54(46,47)48)22-10-25-29(12-27(22)38-36)52-30-13-28-23(20(17-55(49,50)51)15-37(3,4)39-28)11-26(30)33(25)21-6-5-18(9-24(21)34(43)44)35(45)53-40-31(41)7-8-32(40)42/h5-6,9-15,38H,7-8,16-17H2,1-4H3,(H,43,44)(H,46,47,48)(H,49,50,51)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Sacubitril} site|{Sacubitril} Neprilysin|{Sacubitril} Protocol|{Sacubitril} Purity|{Sacubitril} supplier|{Sacubitril} Epigenetic Reader Domain} |Shelf Life: ≥12 months if stored properly.PMID:28038441 |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Excitation maximum=560±20 nm; emission maximum=610±20 nm. Proteins labeled with the TFAX 568 dye is several-fold brighter than the same proteins labeled with lissamine rhodamine B dye.|Products are for research use only. Not for human use.|